The FDA Allows AI Tools to Predict Breast Cancer Risk
The U.S. Food and Drug Administration (FDA) has given the green light to an artificial intelligence (AI) tool designed to estimate the risk of breast cancer. This approval is a significant step toward enhancing early detection methods.
Clairity, the tech company behind Clarity Breast, has developed this new AI platform, which leverages imaging from routine mammograms to forecast breast cancer risk over a five-year period. The company plans to roll out the platform across various health systems by 2025.
Usually, traditional risk assessment models hinge on factors like age and family history. However, it’s noteworthy that around 85% of breast cancer cases occur in women who do not have a family history of the disease. Experts suggest that this is possibly due to genetic changes that are influenced by aging.
Interestingly, existing risk models mostly rely on data from white women in Europe, which may not accurately reflect the diversity of the population. Clairity highlighted that this “ungeneralized” approach could limit its effectiveness for women from various backgrounds.
The AI tool’s function involves analyzing minute details in mammogram images that are linked to breast cancer risk. It provides validated risk scores for healthcare providers to utilize.
Dr. Connie Lehman, a breast imaging expert, emphasized that advancements in AI may unveil important indicators in mammograms that aren’t visible to the human eye. She remarked that accessible and precise risk assessments could greatly aid in early detection efforts, potentially saving lives.
This approval is viewed as a pivotal moment by many in the medical community. Dr. Robert A. Smith from the American Cancer Society mentioned that personalized, risk-based screening is vital for improving outcomes in breast cancer treatment. AI tools, he argues, offer the best chance for achieving this kind of targeted care.
As noted by Larry Norton from the Breast Cancer Research Foundation, the rise of breast cancer diagnoses, particularly among younger women, highlights the need for innovative solutions like Clairity. He underscored the importance of ensuring that women receive appropriate care in a timely manner.
Globally, over 2.3 million women are diagnosed with breast cancer every year, with more than 370,000 cases in the U.S. alone. Alarmingly, cases are rising among women under 50.
Dr. Marc Siegel, a senior medical analyst, described Clairity’s development as “profound.” He pointed out that while radiologists do their best, there are instances where clarification over time is necessary. AI advancements like these can indeed improve the situation tremendously.
Radiologists, particularly in underserved areas, generally endorse the integration of AI in cancer detection. Siegel noted that this technological support is especially crucial in places where radiologists may lack specialized training.
The future certainly looks bright, and while AI will play a significant role in healthcare, it will complement—not replace—human expertise.
